The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Side by side

Compound comparison

Check interactions →Open as saved/share list

AOD-9604

Research chemical · Grade C

Goals
weight-loss, muscle, hormonal
Evidence
6 RCT / 4 animal / 3 in vitro
Routes
injectable-sc
WADA
S2
FDA
Not approved
Cancer caution
none
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

Sermorelin

FDA-approved · Grade C

Goals
muscle, sleep, weight-loss, hormonal
Evidence
0 RCT / 0 animal / 0 in vitro
Routes
injectable-sc
WADA
S2
FDA
Approved
Cancer caution
hard-stop
Typical dose
—
Half-life
Plasma half-life: approximately 10-12 minutes following subcutaneous injection — the shortest half-life of any major GHRH analog in common use
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

Tesamorelin

FDA-approved · Grade B

Goals
weight-loss, muscle, hormonal
Evidence
3 RCT / 0 animal / 0 in vitro
Routes
injectable-sc
WADA
S2
FDA
Approved
Cancer caution
hard-stop
Typical dose
—
Half-life
The result was a compound with a functional half-life of 26-38 minutes — substantially longer than sermorelin, sufficient for once-daily SubQ administration, and with GHRH recep…
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

Cagrilintide

Research chemical · Grade C

Goals
weight-loss, gut
Evidence
3 RCT / 1 animal / 0 in vitro
Routes
injectable-sc
WADA
No
FDA
Not approved
Cancer caution
caution
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →